about
Quinine, an old anti-malarial drug in a modern world: role in the treatment of malariaBiochemical and immunological mechanisms by which sickle cell trait protects against malariaTetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparumArtemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in UgandaAntimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR NetworkFalstatin, a cysteine protease inhibitor of Plasmodium falciparum, facilitates erythrocyte invasionThe structure of chagasin in complex with a cysteine protease clarifies the binding mode and evolution of an inhibitor familyVinyl Sulfones as Antiparasitic Agents and a Structural Basis for Drug DesignStructures of Falcipain-2 and Falcipain-3 Bound to Small Molecule Inhibitors: Implications for Substrate Specificity ‡Polymorphisms in K13 and Falcipain-2 Associated with Artemisinin Resistance Are Not Prevalent in Plasmodium falciparum Isolated from Ugandan ChildrenCommunicable Diseases: A Global PerspectiveSelection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina FasoTemporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in UgandaArtemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan childrenArtemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trialA murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytesBiochemical properties of a novel cysteine protease of Plasmodium vivax, vivapain-4Mining a cathepsin inhibitor library for new antiparasitic drug leadsBlocking Plasmodium falciparum development via dual inhibition of hemoglobin degradation and the ubiquitin proteasome system by MG132Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trialEfficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquineStructural basis for unique mechanisms of folding and hemoglobin binding by a malarial proteaseMalaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts.Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic studyWorld Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria.The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataCritical role of amino acid 23 in mediating activity and specificity of vinckepain-2, a papain-family cysteine protease of rodent malaria parasites.Cross-talk between malarial cysteine proteases and falstatin: the BC loop as a hot-spot target.Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi.Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda.Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.Hemoglobin cleavage site-specificity of the Plasmodium falciparum cysteine proteases falcipain-2 and falcipain-3.Regulatory elements within the prodomain of Falcipain-2, a cysteine protease of the malaria parasite Plasmodium falciparumOn-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility.Comparison of the antiplasmodial and falcipain-2 inhibitory activity of beta-amino alcohol thiolactone-chalcone and isatin-chalcone hybrids.Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.Functional evaluation of Plasmodium export signals in Plasmodium berghei suggests multiple modes of protein exportImpact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial.Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on Plasmodium Falciparum Drug Sensitivity-Associated Haplotypes in Uganda.
P50
Q17485067-A5304387-B095-4F5A-B872-DA6ACE097209Q21034104-16D71C9C-E50F-42D9-9B53-F7C531991860Q24674922-3765F9DB-5B53-486F-AF44-BD2CAE82A8FBQ24815752-2251C6A1-D33A-4866-98C2-582D99C74710Q26799713-889EAC95-1966-4F10-BC82-B563BCCCB4DAQ27230072-BD54231A-C60C-41EE-8298-378C331DFDADQ27644771-7B7772C3-E528-4E7E-B91D-D38CB54C05EDQ27646557-F83E0F34-D25C-4E0A-8C02-3DB3BB8B88A9Q27653357-BC923A97-ABBF-455C-91B8-7B6DB9EF809BQ27861962-1E5735CC-68F4-4010-9E94-A5D25E9E3F30Q27928052-FE496359-9895-49F1-B2EC-27DC58114521Q28125901-8C22A74C-A86B-4C91-A242-8518D79847BEQ28125904-2A4A17D6-9EF5-4D26-A624-52B2AF647D38Q28263182-42963602-A177-4F3A-9C7D-B7FCF588B5C1Q28469217-3AACF7AA-75E8-4153-9336-6A8129E785B9Q28472751-71226C47-F488-412B-8E3F-F8740F827D2EQ28475731-E4246881-1EE3-4957-9F85-5AB62C1787A8Q28478016-42A2B5A4-B7DF-43D5-B6F4-36A5850262B9Q28536452-229EF246-A50C-4538-B238-7851B849981FQ28541598-349D2DFD-4387-4201-A432-E1D167CB21DAQ28542034-10760F05-829D-4025-9E57-345F4C6846D2Q28914748-83C502C1-E35A-4A5D-958E-5B2EC189B7F4Q30226671-BFEEDE05-66B5-45AB-91F6-504C49E91C36Q30389796-FA22CA9C-E08F-4139-8EBB-C2471230132EQ30483555-48E95EAF-5B8C-4414-BCF5-22993578879CQ30936416-1113C968-E180-4F1B-BE08-DB3F3DDF40F1Q31102747-24461A31-A4BD-481D-B85E-0E1DE5F1ABB0Q31156352-191109F8-F157-4A8C-9D06-2A8911ABACC8Q33203203-AC5B1A2E-31C8-44C8-A738-C362C6D86182Q33251914-2EE7AB3B-05FA-44A4-8F71-27ACCF391B00Q33342827-AE070E36-31C6-4B12-B37E-C9B5DB68A5B1Q33428555-793063E8-CED3-4577-A1C1-D9B0167D9F62Q33455669-08F007A4-C8B2-43E2-8A11-7ACA8C623341Q33498051-BC430FB2-AD6B-4F59-BB34-252F8F181DF7Q33507529-8392F364-A9D6-463C-9317-1FAD64C4FD4CQ33537541-53C834F8-A4A1-431E-8046-47133A1CD276Q33559051-F084FD28-732B-42DF-902E-F4897B81C98BQ33564232-B6C96C9D-0C06-4A60-8F15-ADFB3A1D8366Q33588501-0F20A54B-A7AE-4A14-AB82-42BFC07BEE60Q33629027-834DA15A-DF4A-46CF-BDF6-A6A26ADD2A64
P50
name
Philip J Rosenthal
@ast
Philip J Rosenthal
@en
Philip J Rosenthal
@nl
type
label
Philip J Rosenthal
@ast
Philip J Rosenthal
@en
Philip J Rosenthal
@nl
prefLabel
Philip J Rosenthal
@ast
Philip J Rosenthal
@en
Philip J Rosenthal
@nl